Immusoft Reports Promising Early Data for Lead Candidate in MPS I
Nearly a year after making cell therapy history by dosing the first patient with the first engineered B cell in a human trial, Immusoft has reported promising but early clinical data showing its lead candidate was effective nine months after dosing, as well as safe. Immusoft has presented data from its Phase I trial (NCT05682144) assessing ISP-001 nine months after administering a single low dose of 2.5 x 107 cells/kg in a patient with mucopolysaccharidosis type I (MPS I). The data showed the patient—identified as a man in his mid-20s—to have pharmacodynamic, functional, reported quality of life, and daily living activity improvements, as well as reduced pain associated with MPS I. Read more >>